The Mojanda–Fuya Fuya Volcanic Complex consists of two nearby volcanoes, Mojanda and Fuya Fuya. The older one, Mojanda volcano (0.6 to 0.2 Ma), was first constructed by andesites and high-silica ...andesites forming a large stratovolcano (Lower Mojanda). This edifice was capped by a basaltic andesite and andesitic cone (Upper Mojanda), which collapsed later to form a 3-km-wide summit caldera, after large phreatomagmatic eruptions. The Lower Fuya Fuya edifice was constructed by the extrusion of viscous Si-rich andesitic lavas and dacitic domes, and the emission of a thick sequence of pyroclastic-flow and fallout deposits which include two voluminous rhyolitic layers. An intermediate construction phase at Fuya Fuya is represented by a mainly effusive cone, andesitic in composition (San Bartolo edifice), the construction of which was interrupted by a major sector collapse in the Late Pleistocene. Finally, a complex of thick siliceous lavas and domes was emplaced within the avalanche amphitheatre, forming the Upper Fuya Fuya volcanic centre. This paper shows that the general evolution from an effusive to an explosive eruptive style is related to a progressive adakitic contribution to the magma source. Although all the rocks of the complex are included in the medium-K field of continental arcs, the Fuya Fuya suite (61–75 wt.% SiO
2
) shows depletion in Y and HREE and high Sr/Y and La/Yb values, compared to the less silicic Mojanda suite (55–66.5 wt.% SiO
2
). The Mojanda calc-alkaline suite was generated by partial melting of an adakite-metasomatised mantle source that left a residue with 2% garnet, followed by fractional crystallization of dominant plagioclase + pyroxene + olivine at shallow, intra-crustal depths. For Fuya Fuya, geochemical and mineralogical data suggest either (1) partial melting of a similar metasomatised mantle with more garnet in the residue (4%), followed by fractional crystallization involving plagioclase, amphibole and pyroxene, or (2) mixing of mafic mantle-derived magma from the Mojanda suite and slab melts, followed by the same fractional crystallization process.
Piel en el siglo XXI Pedro Lobos, B.; Gonzalo Eguiguren, L.
Revista Médica Clínica Las Condes,
November 2011, 2011-11-00, 2011-11-01, Letnik:
22, Številka:
6
Journal Article
Recenzirano
Odprti dostop
En el campo de la dermatología en los últimos años se han producido grandes avances en el diagnóstico y tratamiento de las enfermedades cutáneas.
La extensión del tegumento, su gran diversidad ...celular y su fácil accesibilidad han estimulado la realización de múltiples estudios e investigación. De gran relevancia han sido los que han utilizado células madre mesenquimáticas de la piel, ya que tendrán un gran impacto en la medicina de este siglo en relación al aporte terapéutico que esto implica.
La farmacogenética, que es el estudio del efecto de la variabilidad genética en un individuo para aumentar las posibilidades de una respuesta terapéutica y disminuir las chances de una reacción adversa a drogas, se acerca al ideal de una medicina personalizada y se ha constituido en una realidad en algunas enfermedades de la piel. Finalmente la fotonanodermatología (interface entre fotobiología, dermatología y nanotecnología), es una tecnología que ha crecido rápidamente en el campo de la medicina y especialmente la dermatología, donde tiene aplicaciones múltiples tanto en productos para la protección de la piel, como en el diagnóstico y tratamiento de enfermedades cutáneas.
In the dermatology field in the last years, there have been great advances in the diagnosis and treatment of cutaneous diseases. The skin with their large surface and easy accesibility has stimulated the realization of multiplestudies and research.
The skin mesenchymal stems cells research is expected to have a great impact on the medicine of the 21st century, specially related with their therapeutic implications.
Pharmacogenetics refers to the study of the genetic variability between patients that is been used to optimizate drug efficacy, minimizing toxicity is near the ideal of a personalized medicine and it is being used in some skin diseases. Finally photonanodermatology (interface of photobiology, dermatology and nanotechnology) is a technology that has grown quickly in medicine and specially dermatology, where it has multiple uses in skin protection products and in diagnosis and treatment of skin diseases.
Despite the use of pneumococcal vaccine and prophylactic oral penicillin, septicemia due to infection with Streptococcus pneumoniae remains a major cause of morbidity and mortality among young ...children with sickle cell disease
1
. Traditionally, febrile children with sickle cell disease have routinely been hospitalized for the prompt administration of high-dose parenteral antibiotics to treat potentially fatal septicemia
2
. Each such admission represents a disruption in the lives of the patients, who may be psychologically affected by repeated hospitalizations, and their parents, who may lose time from work and find their jobs in jeopardy. Furthermore, the expenditure of health care resources . . .
Organic osmolyte and halide permeability pathways activated in epithelial HeLa cells by osmotically induced cell swelling are studied using electrophysiological and radiotracer efflux techniques.
Organic osmolyte and halide permeability pathways activated in epithelial HeLa cells by cell swelling were studied by radiotracer efflux techniques and single-cell volume measurements.
El sistema de justicia hoy de Belaunde L. de R., Javier; Pásara, Luis; Eguiguren Praeli, Francisco José ...
THEMIS: Revista de Derecho,
2010
58
Journal Article
To determine the risk and pertinent features of non-Hodgkin's lymphoma (NHL) as a second malignancy, medical records were searched of 5484 consecutive children treated for various malignancies at a ...single institution during a 27 year period. Of these, three have developed secondary NHL. The probability of secondary NHL in this cohort at 5 and 10 years after the diagnosis of the first malignancy was 0.05% (95% confidence interval, 0.01%, 0.2%) and at 15 years 0.16% (0.04%, 0.63%). With 30710 person-years observed, the risk in this cohort was 9.8 per 100,000 person-years. A literature search disclosed variously detailed descriptions of 21 cases of secondary NHL in patients whose primary malignancy had been diagnosed when they were less than 20 years old. Of 18 cases with documented secondary NHL histology, the most common subtypes were large cell (n = 7) and small non-cleaved cell (n = 6); mixed histology was found in three and lymphoblastic in two cases. Twenty-three of 24 children with secondary NHL had initial lymphohematopoietic neoplasms: Hodgkin's disease (n = 18), acute lymphoblastic leukemia (n = 4) and acute myelogenous leukemia (n = 1); the remaining child had astrocytoma. Of 18 patients (including three cases from this institution) with known outcome, only four were reported to be alive at 5+, 6+, 12+ and 96+ months, respectively. Secondary NHL occurs most often after therapy for Hodgkin's disease and confers a dismal prognosis.
PDF
